RIMS2

Across TCGA pan-cancer cohorts, RIMS2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated RIMS2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RIMS2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated RIMS2 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

STAD, ESCA, and UCS are the cancer types where RIMS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.920	0.329	<.001	41	view →
ESCA	OS	Median	All	0.229	0.580	<.001	36	view →
UCS	OS	Median	II,III,IV	0.001	0.616	<.001	24	view →
KIRP	OS	Median	All	0.111	0.707	<.001	24	view →
LUAD	OS	Median	III,IV	0.231	0.560	.005	18	view →
LUSC	DFS	Median	II,III,IV	0.546	0.731	.002	18	view →
SKCM	DFS	Median	II,III,IV	0.835	0.641	.004	10	view →
ACC	DFS	Median	IV	0.010	0.383	<.001	9	view →
DLBC	OS	Median	All	0.053	0.936	<.001	8	view →
UCEC	DFS	Median	All	0.729	0.629	.033	8	view →
COAD	OS	Median	All	0.395	0.683	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RIMS2–STAD (OS)

Open the STAD breakdown →